Pfizer's RSV vaccine, Abrysvo, demonstrated robust immune responses in young adults aged 18 to 59 with underlying health conditions, mirroring older age groups' reactions, paving the way for broader U.S. approval.
The adult vaccine market for RSV is projected to reach $11 billion by 2032, presenting a lucrative opportunity for companies like Pfizer, especially as demand for COVID-19 shots diminishes.
Pfizer's CEO is committed to expanding the market share of the RSV vaccine in 2024, with current approval for adults 60+ and pregnant women; ongoing trials target high-risk populations like immunocompromised adults.
[
add
]
[
|
|
...
]